News

Bellerophon Therapeutics has enrolled the first patient in a Phase 2b clinical trial evaluating INOpulse as a treatment for pulmonary hypertension associated with interstitial lung disease, or PH-ILD. The trial (NCT03267108) will assess the safety and effectiveness of Bellerophon’s pulsed, inhaled nitric oxide treatment for people with PH-ILD, including…

Important research findings, therapy advances, and other events related to pulmonary hypertension were reported daily in Pulmonary Hypertension News during 2017. Now that the year is over, it’s time to briefly review the articles that appealed most to our readers. Here are the Top 10 most-read articles of 2017, with a brief description of…

A group of clinician-researchers with expertise in the field of cardiovascular and pulmonary diseases propose in a commentary that guidelines for the diagnosis of pulmonary hypertension (PH) should be changed to include patients who may be at risk of developing the disease. The researchers contend that a broader definition of PH…

Tracleer (bosentan) may be of significant benefit to people with borderline or less severe pulmonary hypertension (PH) due to idiopathic pulmonary fibrosis (IPF), results from an ongoing clinical trial suggest. According to interim data collected from the Japanese study, Tracleer — an approved therapy for pulmonary…

The first healthy participants have been injected with CAM2043 (treprostinil FluidCrystal Injection Depot) in a Phase 1 study assessing the treatment’s safety, tolerability, and pharmacokinetics in both single and repeated doses, the Swedish pharmaceutical company Camurus announced. CAM2043 contains treprostinil, a therapy that is effective for treating pulmonary…

A report about life with pulmonary arterial hypertension (PAH) as a young person, created by young patients worldwide, addresses issues both pertinent and challenging to this age group — 18 to 30 — whose particular needs beyond the physical can often be overlooked. These issues range from choosing a…

Echocardiograms can identify infants at risk of developing pulmonary hypertension, especially babies who are underweight, a German study reports. Early treatment can eliminate PH in many newborns, the study added. The research, in the journal Neonatology, is titled “An Echocardiographic Screening Program Helps to Identify Pulmonary Hypertension…

Patients with blood clots in the lungs known as chronic thromboembolic pulmonary hypertension (CTEPH) can benefit from balloon pulmonary angioplasty (BPA), a new study shows. The procedure is an alternative to the standard treatment for CTEPH — pulmonary endarterectomy (PEA) — in patients who are not eligible…

Scleroderma patients with newly diagnosed pulmonary arterial hypertension (PAH) have significantly higher healthcare costs than those without PAH, a Colorado study shows. The researchers said scleroderma patients with interstitial lung disease (ILD) also face higher costs. Both lung conditions are associated with poorer scleroderma patient survival, demonstrating the  need for…

SteadyMed Therapeutics will do more testing to answer American regulators’ questions about the safety and effectiveness of its PatchPump pulmonary hypertension therapy delivery device. The U.S. Food and Drug Administration rejected the company’s New Drug Application for the device, which delivers Trevyent (treprostinil). It said SteadyMed needs to submit…

A single-dose of Ventavis (inhaled iloprost) is safe and effective in treating pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD), with greatest efficacy seen in patients with severe PH, a study by researchers in China reports. The study “Hemodynamic and gas exchange effects of…

The Pulmonary Hypertension Association (PHA) has unveiled eligibility criteria for patients and caregivers applying for stipends to attend next year’s PHA International PH Conference and Scientific Sessions in Orlando, Florida. The event, set for June 29 to July 1, is open to pulmonary hypertension (PH) patients, their caregivers and community…